CompletedPhase 2NCT04604652

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: HighTide Biopharma Pty Ltd
Principal Investigator: Adrian DiBisceglie, MD
HighTide Therapeutics Biopharma Pty.
Intervention: HTD1801 (BUDCA)(drug)
Enrollment: 24 target
Eligibility: 18-75 years · All sexes
Timeline: 2021 – 2022

Study locations (12)

University of Miami Schiff Center for Liver Disease, Miami, Florida, United States
Piedmont Healthcare, Atlanta, Georgia, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Henry Ford Health Services, Detroit, Michigan, United States
St. Louis University, St Louis, Missouri, United States
Northshore University Hospital, Manhasset, New York, United States
University GI, Providence, Rhode Island, United States
Baylor Research Institute, Dallas, Texas, United States
The Texas Liver Institute, San Antonio, Texas, United States
Liver Institute of Virginia, Newport News, Virginia, United States
Bon Secours Liver Institute of Richmond, Richmond, Virginia, United States
Liver Institute Northwest, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04604652 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials